Skape Bio ApS

Pioneering AI-designed miniproteins to unlock previously inaccessible GPCR drug targets

Skape Bio is a Copenhagen-based biotechnology company founded in 2025 by Chris Norn, PhD, and co-founders including Nobel Laureate Dr. David Baker and scientists from the Institute for Protein Design at the University of Washington and the BioInnovation Institute in Copenhagen. The company is advancing GPCR therapeutics through a proprietary platform that integrates generative protein design, deep evolutionary insights, and high-throughput in-cell screening to create de novo designed miniprotein agonists and antagonists with validated atomic-level accuracy. By eliminating the need for receptor solubilization or mutation and enabling screening in native membrane environments, Skape Bio addresses longstanding challenges in GPCR drug discovery. Its competitive advantage lies in uniting AI-driven protein engineering with scalable human-cell screening in a single integrated platform. Skape Bio aims to expand therapeutic access to difficult GPCR targets and establish a next-generation pipeline of precision biologics through strategic partnerships with pharmaceutical companies and investors.